Bempedoic Acid
Tolvaptan
May 14, 2025Bempedoic Acid (API): A Breakthrough in Cholesterol Management | Valence Labs
In the evolving landscape of cardiovascular health, Bempedoic Acid (API) has emerged as a promising therapeutic advancement, especially for patients who are intolerant to statins. As the demand for effective cholesterol-lowering therapies increases, Valence Labs stands at the forefront as a trusted manufacturer and supplier of high-quality Bempedoic Active Pharmaceutical Ingredient (API) in India and global markets.
What is Bempedoic Acid (API)?
Bempedoic Acid is a novel lipid-lowering agent used in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). Unlike traditional statins, Bempedoic works upstream in the cholesterol biosynthesis pathway, offering a unique mechanism with reduced muscle-related side effects.
It is an oral, once-daily medication that has shown efficacy in reducing LDL-C (low-density lipoprotein cholesterol) levels in patients who are either statin-intolerant or require additional LDL-C reduction.
Mechanism of Action
Bempedoic Acid works by inhibiting the enzyme ATP citrate lyase (ACL)—a key enzyme in the cholesterol synthesis pathway. It reduces cholesterol production in the liver and increases LDL receptor expression, thereby enhancing the clearance of LDL-C from the bloodstream.
What sets Bempedoic apart is that it is activated only in the liver and not in the muscles, which significantly reduces the risk of muscle pain or damage—a common issue with statins.
Clinical Applications
- Primary Hypercholesterolemia (Familial and Non-Familial)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Statin-intolerant patients requiring LDL-C reduction
- Combination therapy with ezetimibe or statins for enhanced cholesterol management
Global Market Demand for Bempedoic Acid API
The global demand for Bempedoic is surging, driven by increasing prevalence of cardiovascular diseases and statin intolerance among patients. According to recent market research:
- The global Bempedoic market is expected to grow at a CAGR of over 10% between 2023 and 2030.
- Its potential is particularly high in North America, Europe, India, and Southeast Asia.
- Growing awareness about statin intolerance is fueling demand for alternative therapies like Bempedoic Acid.
Why Choose Valence Labs for Bempedoic Acid API?
At Valence Labs, we are committed to delivering high-purity, GMP-certified APIs that meet international standards. Here’s what sets us apart as a leading Bempedoic API manufacturer and supplier:
High Purity and Quality Standards
- Produced under strict GMP, WHO-GMP, and ISO guidelines
- Controlled impurity profile for maximum therapeutic efficacy
- Compliance with ICH and pharmacopeial standards
End-to-End Manufacturing Capabilities
- In-house R&D and pilot-scale production
- Scalable batch manufacturing to meet bulk requirements
- Regulatory support with documentation (DMF, COA, MSDS, etc.)
Global Supply Chain
- Robust export network to over 20 countries
- On-time delivery with efficient logistics and temperature-controlled packaging
- Strategic partnerships with pharma formulation companies
Custom Manufacturing & Technical Support
- Tailor-made solutions for clients’ specific formulation needs
- 24/7 technical support and regulatory assistance
Applications in Formulations
Bempedoic is typically used in formulations like:
- Tablets (180 mg)
- Fixed-dose combinations with Ezetimibe or statins
- Investigational combinations with SGLT2 inhibitors for patients with diabetes and cholesterol issues
Our API is suitable for both branded formulations and generic product development, making it an attractive choice for formulation manufacturers.
Future Outlook
With increasing lifestyle-related disorders and cardiovascular issues, the need for effective and safe cholesterol-lowering drugs will only rise. Bempedoic has the potential to redefine lipid-lowering therapy, and Valence Labs is proud to play a pivotal role by offering reliable and consistent API supply for global pharmaceutical companies.
Conclusion
The introduction of Bempedoic API marks a major milestone in the pharmaceutical industry’s fight against cardiovascular diseases. With its distinct mechanism of action, excellent safety profile, and increasing global acceptance, it represents a great opportunity for formulators and pharmaceutical marketers alike.
Contact Information
Contact Valence labs, if you want to get any details regarding Bempedoic Acid Or any other details regarding our company.
- Company Name: Valence Labs
- Company Address: Valence Labs Pvt Ltd, Village Jansui, Mirzapur-Jansui Road, Rajpura, Punjab 140401
- Phone Number: +91-98156 66305
- Email:Â info@valencelabs.co
- Website:Â www.valencelabs.co
FAQs about Bempedoic Acid (API)
- Q: What is the CAS number of Bempedoic Acid?
A: The CAS number for Bempedoic Acid is 738606-46-7. - Q: Is Bempedoic Acid API suitable for statin-intolerant patients?
A: Yes, Bempedoic Acid is particularly beneficial for patients who cannot tolerate statins due to muscle pain or other side effects, as it is not activated in muscle tissues. - Q: What is the typical dosage in finished formulations?
A: The standard dosage of Bempedoic Acid in finished formulations is 180 mg once daily, either alone or in combination with other cholesterol-lowering agents. - Q: Can Valence Labs supply Bempedoic Acid for international markets?
A: Absolutely. Valence Labs exports high-quality Bempedoic Acid API to multiple international markets, ensuring compliance with global regulatory standards. - Q: Do you provide technical documents like DMF or MSDS?
A: Yes, we provide essential regulatory documentation including DMF (Drug Master File), MSDS (Material Safety Data Sheet), COA (Certificate of Analysis), and other necessary documents. - Q: What packaging options do you offer for bulk Bempedoic Acid API?
A: We offer customized bulk packaging options such as HDPE drums and double-layered polythene liners to ensure product stability and integrity during transportation.
